BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-1.13%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$5.86B
AUM Growth
+$5.86B
(+222%)
Cap. Flow
+$4.03B
Cap. Flow
% of AUM
68.76%
Top 10 Holdings %
Top 10 Hldgs %
42.44%
Holding
219
New
83
Increased
86
Reduced
22
Closed
16
Top Buys
| 1 |
Ionis Pharmaceuticals
IONS
|
$492M |
| 2 |
Incyte
INCY
|
$310M |
| 3 |
Neurocrine Biosciences
NBIX
|
$298M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$239M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
$239M |
Top Sells
| 1 |
WCG
Wellcare Health Plans, Inc.
WCG
|
$29.2M |
| 2 |
Cencora
COR
|
$19.9M |
| 3 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
$16.5M |
| 4 |
WBA
Walgreens Boots Alliance
WBA
|
$14.7M |
| 5 |
Illumina
ILMN
|
$10.9M |
Sector Composition
| 1 | Healthcare | 94.72% |
| 2 | Technology | 0.56% |
| 3 | Industrials | 0.42% |
| 4 | Financials | 0.06% |
| 5 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Gilead Sciences
GILD
$140B
| $72.2M | 1.23% | 1,069,200 +991,400 | +1,274% | +$67M |
|
27
Moderna
MRNA
$9.37B
| $69.2M | 1.18% | +4,724,246 | New | +$69.2M |
|
28
Humana
HUM
$36.5B
| $64M | 1.09% | 241,212 +88,735 | +58% | +$23.5M |
|
|
MYOK
29
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $63.4M | 1.08% | +1,264,913 | New | +$63.4M |
|
30
Boston Scientific
BSX
$156B
| $59.3M | 1.01% | 1,380,782 +233,295 | +20% | +$10M |
|
|
ICPT
31
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $56.6M | 0.97% | 711,803 +694,576 | +4,032% | +$55.3M |
|
|
BOLD
32
DELISTED
Audentes Therapeutics, Inc
BOLD
| $51.9M | 0.89% | +1,369,604 | New | +$51.9M |
|
33
Danaher
DHR
$147B
| $50.1M | 0.86% | 350,698 +8,914 | +3% | +$1.27M |
|
|
ALDR
34
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $48.5M | 0.83% | 4,118,806 +2,832,058 | +220% | +$33.3M |
|
35
UnitedHealth
UNH
$281B
| $47.4M | 0.81% | 194,394 +61,557 | +46% | +$15M |
|
36
Jazz Pharmaceuticals
JAZZ
$7.75B
| $47.4M | 0.81% | 332,173 +64,735 | +24% | +$9.23M |
|
37
Wave Life Sciences
WVE
$1.53B
| $39.5M | 0.67% | +1,515,002 | New | +$39.5M |
|
38
Sangamo Therapeutics
SGMO
$157M
| $39.3M | 0.67% | +3,650,000 | New | +$39.3M |
|
39
Bristol-Myers Squibb
BMY
$96B
| $38.8M | 0.66% | 855,609 +159,785 | +23% | +$7.25M |
|
40
CRISPR Therapeutics
CRSP
$4.71B
| $38.2M | 0.65% | +810,462 | New | +$38.2M |
|
41
Becton Dickinson
BDX
$55.3B
| $37.7M | 0.64% | 149,692 +20,720 | +16% | +$5.22M |
|
|
MYOV
42
DELISTED
Myovant Sciences Ltd.
MYOV
| $35.4M | 0.6% | +3,910,109 | New | +$35.4M |
|
43
Centene
CNC
$14.3B
| $35.4M | 0.6% | 674,525 +499,537 | +285% | +$26.2M |
|
|
ABMD
44
DELISTED
Abiomed Inc
ABMD
| $35.1M | 0.6% | 134,682 +75,293 | +127% | +$19.6M |
|
45
Cigna
CI
$80.3B
| $33.2M | 0.57% | 210,754 +45,097 | +27% | +$7.1M |
|
46
Stryker
SYK
$150B
| $32.7M | 0.56% | 159,163 +10,263 | +7% | +$2.11M |
|
47
Edwards Lifesciences
EW
$47.8B
| $32.1M | 0.55% | 173,966 +12,054 | +7% | +$2.23M |
|
48
Scholar Rock
SRRK
$3.14B
| $31M | 0.53% | +1,951,839 | New | +$31M |
|
49
Qiagen
QGEN
$10.1B
| $30.2M | 0.52% | 744,513 +127,319 | +21% | +$5.16M |
|
|
ITCI
50
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $29.1M | 0.5% | +2,245,500 | New | +$29.1M |
|